Please login to the form below
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Cost-minimisation analysis (CMA)
A form of economic evaluation comparing the costs of alternative interventions that have equal effects.
In Health care, Cost-minimisation analysis (CMA) is an economic appraisal that determines the least costly alternative therapy after the proposed drug has been established to be no more detrimental than its main competitor(s) in terms of capability and toxicity.
See also:
Cost–benefit analysis
Cost-effective (healthcare economics)
Cost-effectiveness league table (healthcare economics)
Cost-effectiveness threshold (health economics)
Cost consequences analysis (CCA)
Related terms
Health technology assessment/appraisal (HTA), Porter's 'Five Forces', Elective care, Phase III trials, Quality of life (QOL), NHS Executive, Phase IV trials, Ad impression , Cost per thousand (CPM), Advertising research, Preferred provider organisation (PPO), Brief summary, Association of the British Pharmaceutical Industry (ABPI), Cost-effectiveness (in media/advertising), Continuing professional development (CPD),
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
- Recognising HIV Vaccine Awareness Day
- Scientists discover new approach to treat brain tumours
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Part 1 of the Medscape video interview series
- NHS England appoints Chris Hopson as its new chief strategy officer
- Almirall launches Actinic Keratosis Global Day during Skin Cancer Awareness Month
- Pfizer/BioNTech COVID-19 vaccine produces strong immune response in children
- AbbVie submits Parkinson’s disease therapy to FDA
- When is an agency not an agency?
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Kim Lemon appointed head of Liberation Unlimited
- Perrigo expands consumer health with €3.6bn Omega purchase
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- We’ll need more than a spoonful of sugar to counter vaccine hesitancy
PMHub
Cegedim Health Data
Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...
